rs2575876 — ABCA1

ABCA1 rs2575876 — A Recessive Dimmer Switch on Cholesterol Efflux

ABCA1¹¹ ATP-Binding Cassette Transporter A1 — a large cell-membrane protein that pumps cholesterol and phospholipids out of cells onto lipid-poor apolipoprotein A-I, the initiating step for HDL particle assembly is the rate-limiting controller of reverse cholesterol transport²² reverse cholesterol transport
the pathway by which excess cholesterol is ferried from peripheral tissues back to the liver for recycling or excretion. When ABCA1 works well, cells shed cholesterol efficiently, nascent HDL forms rapidly, and cardiovascular risk declines. rs2575876 is a common intronic variant in the ABCA1 gene on chromosome 9 that modulates this process in a dose-dependent way — but its most clinically significant effect emerges primarily when both copies carry the A allele.

The Mechanism

rs2575876 sits within an intron of ABCA1 at GRCh38 position 104,903,458. The ABCA1 gene transcribes from the minus strand, so the alleles reported by genome sequencing files (plus strand) are G (reference) and A (alternate). This is a non-coding variant with no direct amino acid change. Its location within the intron places it in a region rich in regulatory elements that have been shown to fine-tune ABCA1 transcription in hepatocytes and other tissues.

The neighboring variant rs2575875³³ rs2575875
a closely related intronic SNP in LD with rs2575876 and rs4149268 in this ABCA1 locus, studied by Howard et al.⁴⁴ Howard et al.
Howard et al. Allele-specific enhancers mediate associations between LCAT and ABCA1 polymorphisms and HDL metabolism. PLOS One, 2019, sits in a transcriptional enhancer that creates an allele-specific STAT3⁵⁵ Signal Transducer and Activator of Transcription 3 — a transcription factor activated by cytokines that loops from intronic enhancers to the ABCA1 promoter, driving hepatic expression binding site. These regulatory variants in tight LD form a haplotype block in which the cumulative effect of homozygosity matters more than any single base change. AA homozygotes at rs2575876 sit at the weaker end of this regulatory spectrum.

The Evidence

The strongest direct evidence comes from a cohort study by Lin et al.⁶⁶ Lin et al.
Lin et al. Association between high-density lipoprotein and functional outcome of ischemic stroke patients in a Taiwanese population. Lipids Health Dis, 2024 of 1,310 first-ever acute ischemic stroke patients. Among two ABCA1 SNPs tested, rs2575876 and rs1883025 were the only two significantly associated with HDL-C levels in the total population and in sex-stratified subgroups. Under a recessive model — AA versus GG+GA combined — rs2575876 AA homozygotes showed measurably different HDL-C levels and a significantly elevated risk of poor functional outcomes at 1 and 3 months post-stroke, particularly when HDL-C was simultaneously abnormal (too low or too high). This recessive pattern implies that a single A allele is largely compensated by the G allele, but two A alleles expose the full effect of reduced ABCA1 regulatory activity.

Genome-wide association data add breadth: multiple large GWAS including the Global Lipids Genetics Consortium (>1.65 million individuals) have identified the ABCA1 locus on chromosome 9 as genome-wide significant for triglycerides and LDL-C, with rs2575876 named as one of the contributing tag SNPs for both traits. Effect sizes are modest — typical of common intronic regulatory variants — but consistent across diverse ancestries.

A broader review by Frikke-Schmidt⁷⁷ Frikke-Schmidt
Frikke-Schmidt R. Genetic variation in the ABCA1 gene, HDL cholesterol, and risk of ischemic heart disease. Atherosclerosis, 2010 underscores an important nuance: while ABCA1 variants lower HDL-C, genetically low HDL per se does not straightforwardly predict ischemic heart disease risk. The ABCA1-IHD association appears to be partially independent of HDL levels, suggesting ABCA1 has cardioprotective roles beyond cholesterol efflux capacity alone.

Practical Actions

Because the AA genotype is present in only about 5–6% of the population globally, most people carry at least one G allele and will not face the full recessive effect. For AA homozygotes, the priority is monitoring HDL-C and addressing any confirmed deficit through strategies known to improve ABCA1-driven cholesterol efflux: reducing trans fat intake (trans fats directly suppress ABCA1 expression), substituting monounsaturated and omega-3 fats, and sustaining aerobic exercise. If HDL remains below target despite lifestyle efforts, niacin-based options can raise HDL substantially.

The stroke interaction finding signals that when HDL-C goes outside the normal range in AA carriers, recovery from vascular events is compromised. Maintaining HDL-C within normal bounds is therefore especially important for this genotype.

Interactions

The two ABCA1 SNPs most co-studied with rs2575876 are rs1883025 (a nearby variant on the same haplotype block) and rs4149268 (an upstream intronic variant in the same regulatory region). All three tag overlapping ABCA1 regulatory signals; carrying risk alleles across multiple ABCA1 loci may have an additive dampening effect on ABCA1 expression and HDL biogenesis. The R219K missense variant rs2230806 acts through a different mechanism — reducing efflux protein function rather than expression — and may compound the effect of intronic risk alleles. Any ABCA1 variant in combination with APOE ε4 represents a convergent challenge to brain cholesterol homeostasis, given ABCA1's role in neuronal cholesterol efflux.